Skip to main content
Log in

In vitro susceptibility ofFrancisella tularensis to fluoroquinolones and treatment of tularemia with norfloxacin and ciprofloxacin

  • Notes
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

The in vitro susceptibility of ten strains ofFrancisella tularensis to four fluoroquinolones (ciprofloxacin, norfloxacin, ofloxacin and pefloxacin) was investigated by determining the MBCs of these quinolones. The results were as follows (mean ± SE): ciprofloxacin 0.13 ± 0.03 mg/l, norfloxacin 0.24 ± 0.07 mg/l, ofloxacin 2.16 ± 0.78 mg/l and pefloxacin 0.51 ± 0.50 mg/l. These concentrations can be achieved in clinical practice. In addition, four tularemia patients were treated with an oral regimen of 750 mg ciprofloxacin b.i.d. and one patient with norfloxacin 400 mg b.i.d. The fever experienced by these volunteers vanished within a couple of days and they were able to resume normal work one week after receiving the antibiotics without any relapses later. These in vitro and in vivo results show that orally administered fluoroquinolones are promising antimicrobial agents for the treatment of human tularemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Boyce JM Francisella tularensis (Tularemia). In: Mandell GL, Douglas RG, Bennett JE (ed): Principles and practice of infectious diseases. Churchill Livingstone, New York, 1990, p. 1742–1746.

    Google Scholar 

  2. Alford RH, John JT, Bryant RE Tularemia treated successfully with gentamicin. American Review of Respiratory Diseases 1972, 106: 265–268.

    Google Scholar 

  3. Kaiser AB, Rieves D, Price AH, Gelfand MR, Parris RE, Decker MD, Evans ME Tularemia and rhabdomyolysis. Journal of the American Medical Association 1985, 253: 241–243.

    Google Scholar 

  4. Dienst FT Tularemia. A perusal of three hundred thirty-nine cases. Journal of Louisiana State Medical Society 1963, 115: 114–127.

    Google Scholar 

  5. Evans ME, Gregory DW, Schaffner W, McGee ZA Tularemia: a 30-year experience with 88 cases. Medicine 1985, 64: 251–269.

    Google Scholar 

  6. Wolfson JS, Hooper DC Fluoroquinolone antimicrobial agents. Clinical Microbiology Reviews 1989, 2: 378–424.

    Google Scholar 

  7. Schoenknecht FD, Sabath LD, Thornsberry C Susceptibility tests: special tests. In: Lennette EH, Balows A, Hausler WJ, Shadomy HJ (ed): Manual of clinical microbiology. American Society for Microbiology, Washington, DC, 1985, p. 1000–1008.

    Google Scholar 

  8. Massey ED, Mangiafico JA Microagglutination test for determining and measuring serum agglutinins ofFrancisella tularensis. Applied Microbiology 1974, 27: 25–27.

    Google Scholar 

  9. Syrjälä H Peripheral blood leukocyte counts, erythrocyte sedimentation rate and C-reactive protein in tularemia caused by the type B strain ofFrancisella tularensis. Infection 1986, 14: 51–54.

    Google Scholar 

  10. Foshay L Tularemia: a summary of certain aspects of the disease including methods for early diagnosis and the results of serum treatment in 600 patients. Medicine 1940, 19: 1–83.

    Google Scholar 

  11. Dahlstrand S, Ringertz O, Zetterberg B Airborne tularemia in Sweden. Scandinavian Journal of Infectious Diseases 1971, 3: 7–16.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Syrjälä, H., Schildt, R. & Räisäinen, S. In vitro susceptibility ofFrancisella tularensis to fluoroquinolones and treatment of tularemia with norfloxacin and ciprofloxacin. Eur. J. Clin. Microbiol. Infect. Dis. 10, 68–70 (1991). https://doi.org/10.1007/BF01964409

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01964409

Keywords

Navigation